Bordeaux, France, April 11th, 2022 – YSOPIA Bioscience, a French clinical stage biotechnology company specializing in the research and development of innovative biotherapies based on the gut microbiome, is pleased to announce the appointment of Dr. Jean-Pierre Lehner as Chairman of the Board of Directors. In addition to his new role, Dr. Lehner has accompanied YSOPIA as Chairman of the Scientific Advisory Board since 2018.
Dr. Lehner (MD, INSEAD) served the Pharmaceutical Industry during more than 30 years, where he developed a broad expertise in international clinical development and Medical Affairs. He has an extensive knowledge of Regulatory Affairs, with more than 30 Marketing Authorizations granted by the Food and Drug Administration (FDA) and/or European Medicines Agency (EMA).
As a member of Sanofi’s General Management and Research and Development committees, Jean-Pierre set up innovative approaches for clinical development based on real world data to strategize the clinical development of new products. Since he retired from Industry, Jean Pierre has acted as advisor to several startup companies, connecting them with investors. He is Board Member of several biotech companies in the EU and USA.
In the same category
YSOPIA Bioscience annonce la nomination du Dr. Jean-Pierre Lehner comme nouveau Président du...
Apr 8, 2022more +
Alliance Promotion Microbiote devient une Association et poursuit la structuration de la filière...
Jan 20, 2022more +
YSOPIA Bioscience Announces First Signs of Biological Activity from Phase I Analysis of Xla1, its...
Dec 2, 2021more +